Skip to main content

Table 1 Overview of the identification of co-druggable interactions: co-druggability score examples and their interpretation

From: Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

Healthy MS Treated Score Treatment Affecting? Healthy-like signaling after treatment Interpretation
0 0 0 0 NO YES Healthy-like signaling:
No combination therapy needed
0 0 1 -1 YES NO Un-healthy signaling. Single treatment is affecting: Co-druggable
0 1 0 1 YES YES Healthy-like signaling. Effective single treatment: No combination therapy needed
0 1 1 0 NO NO Un-healthy signaling. Single treatment not affecting: Co-druggable
1 0 0 0 NO NO Un-healthy signaling. Single treatment not affecting: Co-druggable
1 0 1 1 YES YES Healthy-like signaling. Effective single treatment: No combination therapy needed
1 1 0 -1 YES NO Un-healthy like signaling. Single treatment is affecting: Co-druggable
1 1 1 0 NO YES Healthy-like signaling.
No combination therapy needed
  1. Co-druggable: interactions where treatment with the drug alone yielded signaling activity different to that of the healthy-like state. Columns 1–3: Signaling activity of a given interaction as assessed by modeling in healthy, untreated MS and treated MS. Column 4: Co-druggability score calculated based on differences between columns 1-3. Column 5: Difference present between treated and MS signaling. Column 6: Absence of a difference in interaction between healthy and treated signaling. Column 7: Combination of columns 4, 5 and 6 to identify interactions deregulated (i) by the disease and not reverted to healthy state by treatment or (ii) by an off-target signaling effect by the primary drug (see “Methods”)